Selected article for: "Ct value and group comparison"
Author: MOHAMED, N. A.; BAHAROM, N.; WAN SULAIMAN, W. S.; ZAINOL RASHID, Z.; WONG, K. K.; ALI, U. K.; OTHMAN, S. N.; ABD SAMAD, M. N.; KORI, N.; PERIYASAMY, P.; ZAKARIA, N. A.; SUGUMAR, A. N. K.; MOHAMMAD KAZMIN, N. E.; CHEONG, X. K.; SANIMAN, S. M.; ISAHAK, I.
Title: EARLY VIRAL CLEARANCE AMONG COVID-19 PATIENTS WHEN GARGLING WITH POVIDONE-IODINE AND ESSENTIAL OILS: A PILOT CLINICAL TRIAL
  • Cord-id: vygvs1x3
  • Document date: 2020_9_9
    • ID: vygvs1x3
    Snippet: Background: Gargling had been reported to have significant roles in the prevention and treatment of respiratory tract infections. The purpose of this study was to assess the ability of regular gargling to eliminate SARS-CoV-2 in the oropharynx and nasopharynx. Methodology: This pilot, open labeled, randomized, parallel study compared the effect of 30 seconds, 3 times/day gargling using 1% povidone-iodine (PVP-I), essential oils and tap water on SARS-CoV-2 viral clearance among COVID-19 patients
    Document: Background: Gargling had been reported to have significant roles in the prevention and treatment of respiratory tract infections. The purpose of this study was to assess the ability of regular gargling to eliminate SARS-CoV-2 in the oropharynx and nasopharynx. Methodology: This pilot, open labeled, randomized, parallel study compared the effect of 30 seconds, 3 times/day gargling using 1% povidone-iodine (PVP-I), essential oils and tap water on SARS-CoV-2 viral clearance among COVID-19 patients in a tertiary hospital in Kuala Lumpur. Progress was monitored by day 4,6 and 12 PCR (Ct value), gargling and symptoms diary as well as clinical observations. Results: Five confirmed Stage 1 COVID-19 patients were recruited for each arm. The age range was from 22 to 56 years old. The majority were males. Two respondents had co-morbidities, which were asthma and obesity. Viral clearance was achieved at day 6 in 100%, 80%, 20% and 0% for 1% PVP-I, essential oils, tap water and control group respectively. Analysis of 1% PVP-I group versus control group showed significant p-value for comparison of PCR results on Day 4, Day 6 and Day 12. Conclusions: This preliminary study showed that gargling with 1% PVP-I and essential oils show great potential to be part of the treatment and management of Stage 1 COVID-19. Larger studies are required to ascertain the benefit of gargling for different stages of COVID-19 patients. This study was registered in clinicaltrial.gov (NCT04410159).

    Search related documents:
    Co phrase search for related documents
    • abnormal chest radiograph and low respiratory tract: 1
    • abnormal thyroid and acute sars cov respiratory syndrome coronavirus: 1
    • abnormal thyroid function and acute sars cov respiratory syndrome coronavirus: 1
    • absolute lymphocytic count and lymphocytic count: 1, 2
    • acquire resistance and acute sars cov respiratory syndrome coronavirus: 1, 2, 3
    • active viral replication and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • actual day and acute sars cov respiratory syndrome coronavirus: 1, 2
    • acute sars cov respiratory syndrome coronavirus and additional intervention: 1, 2
    • acute sars cov respiratory syndrome coronavirus and admission finding: 1
    • acute sars cov respiratory syndrome coronavirus and low compliance: 1, 2, 3, 4
    • acute sars cov respiratory syndrome coronavirus and low respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and low respiratory tract: 1, 2, 3, 4, 5
    • acute sars cov respiratory syndrome coronavirus and lung replicate: 1, 2, 3, 4
    • acute sars cov respiratory syndrome coronavirus and lymphocytic count: 1, 2